3B Blackbio DX Ltd

₹1,580.9▲ +8.02%28 Sept

📊 Stock Analysis

Market Data

Market Cap₹1,356.83 Cr.

52W High₹1,750

Current Price₹1,580.9

52W Low₹1,083.5

Down from 52W High9.7 %

Face Value₹10

Performance

ROCE22.8 %

ROE17.12 %

EPS (TTM)₹10.48

EPS Prev Qtr₹11.44

EPS Last Year₹17.55

EBITDA Qtr₹7.18 Cr.

Book Value₹378

Financial Health

Debt/Equity0.01

Debt/Profit0.06

Total Assets₹378 Cr.

Dividend Yield0.32 %

Promoter Holding40.95 %

Earning Power12.51 %

Valuation

Stock P/E24.08

Industry P/E40.99

Price to Book4.18

Price to Sales8.86

Graham Number₹747.49

Key Metrics

__derived

Dividend/Share

₹5

Face Value

₹10

About 3B Blackbio DX Ltd

Healthcare · Healthcare

3B Blackbio DX Ltd is listed on NSE in the Healthcare / Healthcare sector. Face value ₹10. Market cap ₹1,356.83 Cr.

Price Chart

Strengths & Weaknesses

Strengths

The company has a high ROCE of 27.78%, indicating efficient use of capital.
The company boasts a strong ROE of 20.96%, reflecting profitability relative to shareholder equity.
The company is debt-free with a Debt to Equity ratio of 0, reducing financial risk.
The company has a significant promoter holding of 40.95%, indicating strong management control.

Weaknesses

The Dividend Yield is low at 0.39%, which may not attract income-focused investors.
The P/E Ratio of 19.74 may be considered relatively high, suggesting potential overvaluation.
The P/B Ratio of 4.14 is elevated, indicating that the market values the company highly relative to its book value.

Peer Comparison

Name	CMP	P/E	Market Cap	Div Yield	NP Qtr	Qtr Profit Var%	Sales Qtr	Qtr Sales Var%	ROCE%	Debt/Eq
Apollo Hospitals Enterprise Ltd	-	60.97	₹1,27,421.96 Cr	0.23%	₹2,172 Cr	-	₹26,429.9 Cr	-	22.05%	0.6
Max Healthcare Institute Ltd	-	66.77	₹97,411.97 Cr	0.2%	₹1,457.4 Cr	-	₹8,712.05 Cr	-	14.38%	0.27
Manipal Health Enterprises Ltd	-	-	₹94,970.23 Cr	-	-	-	-	-	-	1.25
Aster DM Quality Care Ltd	-	121	₹65,183.66 Cr	0.4%	₹362.82 Cr	-	₹4,876.03 Cr	-	12.95%	0.17
Fortis Healthcare Ltd	-	59.91	₹62,782.32 Cr	0.12%	₹1,070.21 Cr	-	₹9,506.15 Cr	-	13.34%	0.29
Global Health Ltd	-	69.27	₹38,550.84 Cr	-	₹552.33 Cr	-	₹4,683.41 Cr	-	21.87%	0.1
Narayana Hrudayalaya Ltd	-	45.26	₹37,159.95 Cr	-	₹816.55 Cr	-	₹9,072.4 Cr	-	13.65%	1.07
Dr Lal Pathlabs Ltd	-	46.81	₹32,548.55 Cr	1.26%	₹546.3 Cr	-	₹2,890.8 Cr	-	29.55%	0
Krishna Institute of Medical Sciences Ltd	-	150.24	₹32,180.9 Cr	-	₹194.4 Cr	-	₹4,212.5 Cr	-	9.66%	1.44
Poly Medicure Ltd	-	52.64	₹16,587.48 Cr	0.21%	₹312.92 Cr	-	₹1,997.43 Cr	-	15.07%	0.06
Dr Agarwals Health Care Ltd	-	107.57	₹15,991.79 Cr	-	₹185.1 Cr	-	₹2,206.68 Cr	-	16.46%	0.08
Vijaya Diagnostic Centre Ltd	-	82.27	₹15,431.94 Cr	0.13%	₹187.49 Cr	-	₹857.13 Cr	-	36.21%	0
Syngene International Ltd	-	68.32	₹15,167.87 Cr	0.33%	₹221 Cr	-	₹3,600.2 Cr	-	6.95%	0
Indegene Ltd	-	36.68	₹14,769.29 Cr	0.37%	₹400.9 Cr	-	₹3,812.8 Cr	-	17.45%	0
Rainbow Childrens Medicare Ltd	-	48.85	₹13,947.12 Cr	0.25%	₹290.28 Cr	-	₹1,820.14 Cr	-	27.05%	0
Molbio Diagnostics Ltd	-	-	₹13,924.73 Cr	-	-	-	-	-	-	0.35
Park Medi World Ltd	-	38.3	₹11,945.05 Cr	-	₹296.75 Cr	-	₹1,756.29 Cr	-	19.17%	0.11
Metropolis Healthcare Ltd	-	24.51	₹11,863.54 Cr	0.87%	₹202.82 Cr	-	₹1,710 Cr	-	19.8%	0.01
Yatharth Hospital & Trauma Care Services Ltd	-	58.5	₹10,596.57 Cr	-	₹174.45 Cr	-	₹1,334.1 Cr	-	11.7%	0.14
Healthcare Global Enterprises Ltd	-	446.68	₹10,336.94 Cr	-	₹33.26 Cr	-	₹2,627.35 Cr	-	9.41%	0.68

Quarterly Results

📊 Jun 2026: Revenue grew 50.6% YoY, Profit fell 29.0% YoY

	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	22.24	33.9	50.35	35.43	33.49
↳ QoQ Growth	-	+52.4%	+48.5%	-29.6%	-5.5%
Expenses	10.68	19.75	29.01	30.83	26.31
Operating Profit	11.56	14.15	21.34	4.6	7.18
OPM %	51.98%	41.74%	42.38%	12.98%	21.44%
Other Income	4.31	5.51	5.59	10.15	6.14
Interest	0.01	0.04	0.09	0.1	0.1
Depreciation	0.28	0.58	0.38	3.89	1.34
EBITDA	11.84	14.73	21.72	8.49	8.52
EBITDA Margin %	53.24%	43.45%	43.14%	23.96%	25.44%
Profit Before Tax	15.86	19.62	26.84	14.65	13.22
Tax %	20.3%	23.34%	16.39%	33.04%	32.07%
Net Profit	12.64	15.04	22.44	9.8	8.98
↳ QoQ Growth	-	+19.0%	+49.2%	-56.3%	-8.4%
EPS	14.76	17.55	26.19	11.44	10.48

Profit & Loss

	Mar 2026	TTM
Sales	141.92	153.17
Expenses	90.27	105.9
Operating Profit	51.65	47.27
OPM %	36.39%	30.86%
Other Income	25.56	27.39
Interest	0.24	0.33
Depreciation	5.13	6.19
Profit Before Tax	76.97	74.33
Tax %	22.14%	24.3%
Net Profit	59.92	56.26
EPS	69.94	65.66

Compounded Sales Growth

10Y

TTM

Compounded Profit Growth

10Y

TTM

Stock Price CAGR

10Y

12.8%

Return on Equity

10Y

Last Year

20.96%

Balance Sheet

	Mar 2025	Mar 2026
Equity Capital	8.5684	8.57
Reserves	259.8539	315.81
Borrowings	0.31	3.11
Other Liabilities	26.99	50.51
Total Liabilities	295.7184	378
Fixed Assets	7.2186	27.6
CWIP	0	0
Investments	156.31	157.7
Other Assets	132.19	192.7
Total Assets	295.7184	378

Cash Flows

	Mar 2025
Cash from Operating Activity	43.3564
Cash from Investing Activity	-33.8461
Cash from Financing Activity	-3.2193
Net Cash Flow	6.291

Ratios

	Mar 2026
Debtor Days	-
Inventory Days	-
Days Payable	-
Cash Conversion Cycle	-
Working Capital Days	964.17
ROCE %	13.78%

Shareholding Pattern

	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters %	41.28%	41.28%	40.94%	40.95%
FIIs %	2.64%	2.57%	2.57%	2.5%
DIIs %	1.82%	1.87%	1.98%	2.15%
Public %	43.53%	38.09%	37.74%	37.05%
No. of Shareholders	10,709	10,507	10,616	11,049